# Deflox Tablets Bioequivalence (BE) Trial

> **NCT04132583** · PHASE1 · COMPLETED · sponsor: **Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany** · enrollment: 16 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Deflox®
- **DRUG:** Cataflam DD®

## Key facts

- **NCT ID:** NCT04132583
- **Lead sponsor:** Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-21
- **Primary completion:** 2019-10-27
- **Final completion:** 2019-10-27
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2021-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04132583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04132583, "Deflox Tablets Bioequivalence (BE) Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04132583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*